Podcast: China’s Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 5, 2026

Novo Nordisk Weighs Bolt-On Deals As It Looks Past R&D Setbacks
Novo Nordisk CEO Mike Doustdar is signaling bolt-on acquisitions to shore up a pipeline hit by recent trial failures.
Scrip - August 5, 2026

ImmunoAct’s CAR-T Real-World Report Card: Durable Remissions, 98% MSR
ImmunoAct’s NexCAR19 delivers outcomes comparable to Western CAR-Ts at a fraction of the cost. Co-founder Dr Atharva Karulkar breaks down the real-world evidence — drawn from the largest CAR-T dataset in India to date — and the scalable model behind it.
Scrip - August 5, 2026

Hengrui Eyes Fresh NDA For Mounjaro Rival After Second Phase III Diabetes Win
Hengrui’s GLP-1/GIP candidate ribupatide has scored a second win in a late-stage trial in pretreated type 2 diabetes, showing non-inferiority versus Ozempic.
Scrip - August 5, 2026

CagriSema?Setback Takes Shine Off Novo’s FY Forecast Raise
Novo's better-than-expected second-quarter results have given the drugmaker some breathing room, even as a CagriSema miss leaves analysts asking what 2027 could look like.
Scrip - August 5, 2026

Eisai Looks Outward As It Fortifies ‘Omics’ Analysis
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026

BMS Likely Main APAC Beneficiary Of Any AstraZeneca Merger
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026

Amgen Readies Phase III Readouts To Offset Declines In I&I Portfolio
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026

Xeltis Says It Has The Money To Pursue FDA Approval — Just Not For What Comes After
Xeltis has closed €70m in combined financing to pursue FDA approval for its bioresorbable dialysis access graft, but chief executive Eliane Schutte was candid that the money funds the regulatory path — not the commercial one.
Medtech Insight - August 5, 2026

Q&A With Sunscreen Developer On Formulating With BEMT
With the FDA's approval of bemotrizinol ushering in new sunscreen formulation possibilities for the US market, Solésence CEO Kevin Cureton shares his early takeaways on formulating with the first new approved UV filter in over two decades.
HBW Insight - August 4, 2026

P&G Puts Global Footprint On Personalized Supplement Sector With $3.8Bn Thorne Acquisition
Thorne, which for decades focused on practitioner sales following is 1984 launch, says P&G’s acquisition should boost “its mission to become the world's most trusted personalized health brand.”
HBW Insight - August 4, 2026

Could Blister Packs Finally Be Recycled at Scale?
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026

Over The Counter: Realizing Growth Through Pharmacy, With Simon-Kucher
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026

L’Oréal Outlines ‘Ambitious’ Gucci Beauty Plans
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026

Nicotine, Tobacco Researchers Suggest Doctors Recommend E-Cigarettes For Smoking Cessation
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026

Opdivo Biosimilars Gain Ground After EPO Appeal Defeat
BMS has lost its appeal over an Opdivo melanoma dosing patent before the European Patent Office’s Technical Board of Appeal, removing a potential barrier to European biosimilars.
Generics Bulletin - August 5, 2026

Oncology 505(b)(2)s Need Clear Benefits To Win Uptake
In an exclusive interview with Generics Bulletin, McKesson’s Jessica White explains why oncology 505(b)(2) hybrid products need meaningful clinical, operational or supply advantages – alongside early commercial planning – to win provider uptake.
Generics Bulletin - August 5, 2026

Amneal Raises Annual Guidance Amidst Its ‘Most Transformative Period’
As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.
Generics Bulletin - August 5, 2026

The Federated Learning Wave: Part 2, Beyond Proof of Concept
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again.
In Vivo - August 5, 2026